SRDX Key Stats
- SRDX Crosses Below Key Moving Average Level Jun 10
- Why SurModics's Earnings Are Outstanding Fool May 29
- Nasdaq stocks posting largest percentage decreases May 28
- SurModics to Present at the Jefferies Global Healthcare Conference Business Wire May 21
- SURMODICS INC Financials May 17
- 1 Reason SurModics May Be Headed for a Slowdown Fool May 16
- Earnings Volatility Drives These Stocks in a New Direction May 12
- SURMODICS INC Files SEC form 10-Q, Quarterly Report May 10
- SurModics CEO Discuses Q2 2013 Results - Earnings Call Transcript Seeking Alpha May 8
- Earnings Miss at SurModics May 8
SRDX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). SurModics is up 48.63% over the last year vs S&P 500 Total Return up 25.82%, Trinity Biotech up 51.78%, and Abaxis up 39.61%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SRDX
Pro Report PDF for SRDX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SRDX Pro Report PDF
Pro Strategies Featuring SRDX
Did SurModics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.